Von 8 Bewertungen innerhalb der letzten 6 Monate. Dies ist keine Anlageempfehlung.
Kaufen
50%
Halten
38%
Verkaufen
13%
Über
Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.